Nouveau Life Pharmaceuticals (NOUV) Releases Azul Instant™  
6/21/2012 10:22:31 AM

FORT LAUDERDALE, Fla., June 20, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals Inc. (Pink Sheets: NOUV), a provider of quality all-natural dietary supplements, announced today the release of its Azul Instant supplement.

Azul Instant is an all-natural male enhancement supplement for erectile dysfunction (ED) that works in as little as 5 minutes. The supplement's effects can last up to 48 hours. Azul Instant is a doctor-recommended pharmaceutical grade supplement that produces no side effects and promotes a healthy sexual lifestyle. A dose of Azul Instant is one capsule. The supplement is offered in a 5-pack for $24.99 or a 24-pack for $74.99 and can be purchased by visiting the Nouveau Life online store at

"We are so pleased that Azul Instant is now available to the public," stated Nouveau Life CEO Melissa Walker. "There has been tremendous interest in this ED product since its planned production was announced earlier this year. This is our cornerstone product and to have it now on the market makes us very optimistic about the future of Nouveau."

Nouveau Life Pharmaceuticals began manufacturing Azul Instant earlier this spring at an FDA-approved manufacturing facility based in the U.S. The Company plans to distribute Azul Instant through multiple online sales channels, independent retailers, and health professionals.

In addition to Azul Instant, Nouveau Life also offers a daily ED supplement called Azul: Male Enhancer. Both Azul Instant and Azul: Male Enhancer can be purchased by visiting

About Nouveau Life Pharmaceuticals
The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.

Nouveau Life Pharmaceuticals, Inc. - 954-903-2993

SOURCE Nouveau Life Pharmaceuticals, Inc.